MCL Literature Feed

Phospho-flow cytometry reveals that high constitutive AKT and inducible STAT5/SYK B-cell receptor signaling activity predicts shorter survival and ibrutinib resistance, offering a functional biomarker for high-risk MCL.

Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.

This review details BTK inhibitor resistance mechanisms, particularly C481S mutations, and highlights non-covalent BTKi (pirtobrutinib) and PROTACs as key strategies to overcome relapse in MCL.

This large SEER database study identifies being unmarried, particularly widowed, as an independent negative prognostic factor for survival in MCL, underscoring the need for enhanced psychosocial support.

Mendelian randomization analysis reveals that genetically longer telomeres are a causal risk factor for developing hematological malignancies, including MCL, suggesting a potential inherited predisposition for the disease.

Large B-cell lymphoma with IRF4 rearrangement can mimic blastoid MCL by presenting in older adults and expressing CD5, but negativity for Cyclin D1 and SOX11 is crucial for differential diagnosis.

This large retrospective study of orbital lymphomas identifies mantle cell lymphoma as a rare subtype but provides no specific clinical or prognostic data for this particular presentation.

Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.

This preclinical study of a bortezomib nanoparticle delivery system in glioblastoma cell lines is not relevant to mantle cell lymphoma.

Palliative radiotherapy provided profound tumor reduction for an elderly patient with blastoid MCL presenting as a rare oropharyngeal mass, demonstrating a personalized, less-intensive frontline treatment option.

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.

Combining time-limited ibrutinib with CTL019 CAR-T in relapsed/refractory MCL achieved an 80% CR rate with manageable toxicity, showing efficacy even in BTKi-pretreated and TP53-mutated patients.

A Mendelian randomization study provides causal evidence that genetically predicted longer telomere length increases the risk of developing MCL, suggesting a role for enhanced cellular proliferation in pathogenesis.

An AI model using ensemble convolutional neural networks distinguished MCL from CLL and FL on pathology images with 99% accuracy, offering a potential tool for automated histopathological diagnosis.

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

This multi-modal single-cell atlas of the human tonsil provides a high-resolution map of normal B-cell development, enabling a deeper understanding of MCL's cellular origins and heterogeneity.

Targeting the epigenetic modifier KDM5 shows preclinical activity in mantle cell lymphoma, identifying a novel therapeutic vulnerability for potential future treatments.

In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

This case report describes mantle cell lymphoma presenting atypically as erosive duodenitis, highlighting a rare gastrointestinal manifestation that can mimic more common inflammatory conditions.

This case report identifies a rare, leukemic, cyclin D1/SOX11-negative MCL driven by a CCND3::IGH rearrangement, highlighting a diagnostic pitfall and the importance of molecular testing in atypical cases.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

This preclinical study identifies that the miR-17-92 cluster suppresses the tumor suppressor BTG2, leading to B-cell receptor signaling overactivation and suggesting BTG2 as a prognostic biomarker.

PLSCR1 induction by retinoic acid/interferon-α enhances immunogenic cell death in MCL, improving the efficacy of dendritic cell-based vaccines by boosting anti-tumor T-cell responses in vitro.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This case report describes a rare presentation of mantle cell lymphoma as a large right atrial mass, highlighting the potential for significant cardiac involvement and informing differential diagnosis.